| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 165.737 | 181.484 | 223.613 | 305.957 | 356.873 | 405.506 | 425.674 | 466.189 | 570.611 | 596.372 |
| Total Income - EUR | 165.738 | 181.485 | 223.614 | 305.959 | 356.875 | 405.508 | 425.676 | 466.191 | 573.849 | 596.383 |
| Total Expenses - EUR | 156.100 | 171.041 | 206.047 | 288.445 | 342.128 | 349.294 | 373.530 | 421.273 | 509.068 | 553.311 |
| Gross Profit/Loss - EUR | 9.638 | 10.444 | 17.566 | 17.514 | 14.746 | 56.213 | 52.146 | 44.918 | 64.781 | 43.071 |
| Net Profit/Loss - EUR | 7.859 | 8.623 | 15.346 | 14.417 | 11.123 | 52.624 | 48.751 | 41.112 | 59.424 | 36.641 |
| Employees | 4 | 4 | 5 | 7 | 7 | 5 | 6 | 5 | 5 | 6 |
Check the financial reports for the company - Farmacia Adrilaz S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 1.899 | 1.472 | 1.047 | 634 | 286 | 94 | 0 | 0 | 42.550 | 34.553 |
| Current Assets | 70.691 | 68.847 | 103.862 | 117.808 | 122.445 | 151.511 | 169.506 | 162.815 | 220.483 | 212.260 |
| Inventories | 33.235 | 40.594 | 59.530 | 60.308 | 64.649 | 82.211 | 90.596 | 103.664 | 136.229 | 157.669 |
| Receivables | 23.426 | 9.246 | 28.847 | 41.708 | 36.765 | 47.327 | 52.875 | 57.162 | 72.683 | 41.962 |
| Cash | 14.030 | 19.007 | 15.485 | 15.792 | 21.032 | 21.973 | 26.036 | 1.989 | 11.571 | 12.630 |
| Shareholders Funds | 21.631 | 8.667 | 15.986 | 15.045 | 11.174 | 27.866 | 48.799 | 13.160 | 72.544 | 92.979 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 51.454 | 61.652 | 88.923 | 103.939 | 112.088 | 124.087 | 121.047 | 149.996 | 190.829 | 153.834 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Farmacia Adrilaz S.r.l.